NU7441 (KU-57788): Benchmark ATP-Competitive DNA-PK Inhibitor

Executive Summary: NU7441 (KU-57788) is a highly selective, nanomolar-potent inhibitor of DNA-dependent protein kinase (DNA-PK), acting as an ATP-competitive molecule with an IC₅₀ of ~13–14 nM and a Ki of 0.65 nM, and demonstrates minimal inhibition of ATM or ATR up to 100 μM (APExBIO). It is insoluble in water and ethanol but soluble at ≥4.13 mg/mL in DMSO, and is recommended for storage at –20°C [product documentation]. NU7441 sensitizes cancer cells, including HeLa and SW620, to DNA-damaging agents such as etoposide, causing enhanced cytotoxicity and tumor growth delay in xenograft models (Piekna-Przybylska et al., 2019). It induces G1 phase arrest and S phase reduction, especially in p53 wild-type cells, supporting roles in cell cycle modulation and DNA repair research. Compared to other DNA-PK inhibitors, NU7441’s specificity and benchmarked application protocols make it indispensable for preclinical oncology workflows [see comparative review].

Biological Rationale

DNA-dependent protein kinase (DNA-PK) is a serine/threonine kinase essential for the repair of DNA double-strand breaks (DSBs) via non-homologous end joining (NHEJ). Disruption of DNA-PK function impairs genomic stability and cell survival, especially under genotoxic stress. DNA-PKcs (the catalytic subunit) is overexpressed in several tumor types, correlating with resistance to DNA-damaging chemotherapies. Targeted inhibition of DNA-PK is a validated strategy to sensitize cancer cells to radiation and cytotoxic drugs. NU7441 (KU-57788) is a small-molecule chromen-4-one derivative developed to selectively inhibit DNA-PK activity, enabling precise modulation of the DNA damage response pathway in both basic and translational oncology research (APExBIO). DNA-PK also plays a role in immune cell development and viral response, making its inhibition relevant for broader biomedical research (see immune escape applications).

Mechanism of Action of NU7441 (KU-57788) DNA-PK inhibitor

NU7441 acts as a selective, ATP-competitive inhibitor of DNA-PKcs by binding to the kinase’s ATP-binding site. This mechanism blocks substrate phosphorylation and halts NHEJ-mediated DNA repair. The compound exhibits a mean IC₅₀ of 13–14 nM and a Ki of 0.65 nM for DNA-PKcs in cell-free kinase assays. At concentrations up to 100 μM, NU7441 does not significantly inhibit ATM or ATR, highlighting its selectivity. It shows weaker activity against mTOR (IC₅₀: 1.7 μM) and PI3K (IC₅₀: 5 μM), with negligible effects on unrelated kinases. In cellular models, DNA-PK inhibition by NU7441 leads to accumulation of unrepaired DSBs, activation of p53, G1 phase arrest, and increased apoptosis upon exposure to DNA-damaging agents. This mode of action makes NU7441 a robust tool for dissecting DNA repair, cell cycle checkpoints, and synthetic lethality strategies in cancer cells (APExBIO) (Piekna-Przybylska et al., 2019).

Evidence & Benchmarks

• NU7441 (KU-57788) inhibits DNA-PKcs with an IC₅₀ of 13–14 nM and a Ki of 0.65 nM, as shown in in vitro kinase assays (APExBIO).
• Minimal inhibition of ATM and ATR is observed at concentrations up to 100 μM, confirming high specificity (APExBIO).
• NU7441 sensitizes HeLa and SW620 cells to etoposide, increasing cytotoxicity and delaying tumor growth in xenograft models (Piekna-Przybylska et al., 2019).
• Cell cycle analysis shows G1 phase increase and S phase reduction in p53 wild-type cells treated with 1 μM NU7441 for 16 hours (APExBIO).
• NU7441 displays low off-target activity against mTOR (IC₅₀: 1.7 μM) and PI3K (IC₅₀: 5 μM), supporting its use as a selective DNA-PK tool compound (APExBIO).
• DNA-PK inhibition by NU7441 reduces DNA repair efficiency and increases γH2AX signal (a DNA damage marker) in the presence of genotoxic stress (Piekna-Przybylska et al., 2019).

This article extends and updates previous reviews such as "NU7441: Selective DNA-PK Inhibitor for DNA Repair Research" by providing benchmarked protocols and recent evidence of immune context use; it also clarifies selectivity data beyond that discussed in "NU7441 (KU-57788): Precision DNA-PK Inhibition for Immune..." by presenting comparative IC₅₀ values and off-target profiles.

Applications, Limits & Misconceptions

NU7441 (KU-57788) is widely utilized as a DNA repair inhibitor in oncology research, cell cycle arrest assays, and the study of DNA damage response pathways. It is employed to sensitize tumor cells to chemotherapeutics and radiotherapy, dissect caspase signaling, and investigate PI3K/Akt/mTOR pathway crosstalk. Its value extends to studies of immune cell development and viral pathogenesis, including HIV-related DNA repair deficiencies (Piekna-Przybylska et al., 2019). However, several misconceptions and practical limits exist.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: NU7441 is selective for DNA-PKcs and does not broadly inhibit ATM, ATR, or kinases outside the PI3K/mTOR family.
• Solubility constraints: The compound is insoluble in water and ethanol; DMSO (≥4.13 mg/mL) is required for stock solutions.
• Storage instability: NU7441 should be stored at –20°C; long-term storage of solutions is not recommended due to degradation risk.
• Not suitable for chronic exposure: Most in vitro protocols use 1 μM for 16 hours; longer exposures can induce off-target effects.
• Not a direct apoptosis inducer: NU7441 enhances cytotoxicity only in the presence of DNA-damaging agents; it does not directly induce cell death in most models.

Workflow Integration & Parameters

NU7441 is typically applied in vitro at a concentration of 1 μM for 16 hours. For in vivo studies, a dose of 10 mg/kg is administered via intraperitoneal injection. The compound’s solubility in DMSO facilitates compatibility with standard cell culture and animal protocols. Researchers are advised to prepare fresh working solutions and avoid repeated freeze-thaw cycles. Analytical endpoints include γH2AX immunofluorescence, clonogenic survival assays, and cell cycle profiling. Its dual role as a DNA repair inhibitor and cell cycle modulation agent enables integration into combination screening assays with chemotherapeutics or radiation. Detailed troubleshooting and advanced mechanistic strategies are available in recent reviews (see troubleshooting guide) and (see mechanistic deep dive).

Conclusion & Outlook

NU7441 (KU-57788) is a standard-setting, highly selective ATP-competitive DNA-PK inhibitor. Its nanomolar potency, robust selectivity, and validated protocols position it as an indispensable tool for DNA damage response and oncology research. APExBIO provides the A8315 kit, supporting reproducible workflows for both in vitro and in vivo studies. Future directions include combinatorial strategies targeting DNA damage response pathways for enhanced cancer therapy and expanded use in immuno-oncology and neuroinflammation models. For further details, consult the NU7441 (KU-57788) DNA-PK inhibitor product page.